Argenica Therapeutics' (ASX:AGN) ARG-007 Phase 2 trial continues after positive review
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be visible to everyone.
Investor Q&As
Start the conversation
Ask Argenica Therapeutics a question about this update.